ATE154073T1 - Prozess für die herstellung von biologisch aktivem igf-1 durch verwendung von amino-terminal verlängertem igf-1 - Google Patents

Prozess für die herstellung von biologisch aktivem igf-1 durch verwendung von amino-terminal verlängertem igf-1

Info

Publication number
ATE154073T1
ATE154073T1 AT91915251T AT91915251T ATE154073T1 AT E154073 T1 ATE154073 T1 AT E154073T1 AT 91915251 T AT91915251 T AT 91915251T AT 91915251 T AT91915251 T AT 91915251T AT E154073 T1 ATE154073 T1 AT E154073T1
Authority
AT
Austria
Prior art keywords
igf
amino
biologically active
terminal extended
producing biologically
Prior art date
Application number
AT91915251T
Other languages
English (en)
Inventor
Lars Skriver
Kim Ry Hejnas
Henrik Dalboge
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK198990A external-priority patent/DK198990D0/da
Priority claimed from DK249790A external-priority patent/DK249790D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE154073T1 publication Critical patent/ATE154073T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT91915251T 1990-08-20 1991-08-16 Prozess für die herstellung von biologisch aktivem igf-1 durch verwendung von amino-terminal verlängertem igf-1 ATE154073T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK198990A DK198990D0 (da) 1990-08-20 1990-08-20 Biologisk aktivt polypeptid og fremgangsmaade til omdannelse af dette til et modent protein
DK249790A DK249790D0 (da) 1990-10-16 1990-10-16 Fremgangsmaade til renaturering af et humant protein

Publications (1)

Publication Number Publication Date
ATE154073T1 true ATE154073T1 (de) 1997-06-15

Family

ID=26066263

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915251T ATE154073T1 (de) 1990-08-20 1991-08-16 Prozess für die herstellung von biologisch aktivem igf-1 durch verwendung von amino-terminal verlängertem igf-1

Country Status (9)

Country Link
US (3) US5459052A (de)
EP (1) EP0545999B1 (de)
JP (1) JPH06500084A (de)
AT (1) ATE154073T1 (de)
AU (1) AU8417091A (de)
DE (1) DE69126434D1 (de)
IE (1) IE912935A1 (de)
PT (1) PT98711B (de)
WO (1) WO1992003477A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
US5407810A (en) * 1993-08-20 1995-04-18 Genentech, Inc. Aqueous multiple-phase isolation of polypeptide
US5446024A (en) * 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
US5650496A (en) 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
US6756484B1 (en) * 1995-04-14 2004-06-29 Cephalon, Inc. IGF-I purification process
US5747236A (en) 1996-01-26 1998-05-05 Eastman Kodak Company Silver halide light sensitive emulsion layer having enhanced photographic sensitivity
US5747235A (en) 1996-01-26 1998-05-05 Eastman Kodak Company Silver halide light sensitive emulsion layer having enhanced photographic sensitivity
EP0786692B1 (de) 1996-01-26 2004-11-17 Eastman Kodak Company Lichtempfindliche Silberhalogenidemulsionschicht mit gesteigerter photographischer Empfindlichkeit
DE69821294T2 (de) * 1997-07-25 2004-11-18 Eastman Kodak Co. Lichtempfindliche Silberhalogenidemulsionsschicht mit verstärkter photographischer Empfindlichkeit
DE69810853T2 (de) * 1997-07-25 2004-01-22 Eastman Kodak Co. Lichtempfindliche Silberhalogenid-Emulsionsschicht mit erhöhter photographischer Empfindlichkeit
US5994051A (en) * 1997-07-25 1999-11-30 Eastman Kodak Company Silver halide light sensitive emulsion layer having enhanced photographic sensitivity
US6265542B1 (en) * 1997-10-24 2001-07-24 Genentech, Inc. Purification of molecules
US6514682B1 (en) 2001-06-20 2003-02-04 Eastman Kodak Company Speed addendum for photographic emulsions
US20030158593A1 (en) * 2002-02-19 2003-08-21 Heilman Marlin S. Cardiac garment
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
HUE035607T2 (en) 2012-06-25 2018-05-28 Brigham & Womens Hospital Inc Targeted therapeutic agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
DE3611817A1 (de) * 1986-04-08 1987-10-15 Boehringer Mannheim Gmbh Verfahren zur renaturierung von proteinen
DE3618817A1 (de) * 1986-06-04 1987-12-10 Behringwerke Ag Verfahren zur gewinnung aktiver proteine aus einer biologisch inaktiven form
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
JPH03503596A (ja) 1987-06-24 1991-08-15 ノボ・ノルディスク　エー／エス 蛋白質若しくはポリペプチドの調製方法、該ポリペプチドをコードするｄｎａ配列、該ｄｎａ配列およびポリペプチドを有する微生物および該ポリペプチドの薬学的製剤としての利用
JPH01132598A (ja) * 1987-10-14 1989-05-25 Pitman Moore Inc 変性剤溶液中に含まれる組換え蛋白質における分子内ジスルフィド結合の生成を促進する方法
JP2517100B2 (ja) * 1989-03-08 1996-07-24 協和醗酵工業株式会社 ヒト顆粒球コロニ―刺激因子活性を有する蛋白質の精製法
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems

Also Published As

Publication number Publication date
EP0545999A1 (de) 1993-06-16
IE912935A1 (en) 1992-02-26
US5708134A (en) 1998-01-13
US5691168A (en) 1997-11-25
US5459052A (en) 1995-10-17
DE69126434D1 (de) 1997-07-10
PT98711A (pt) 1992-07-31
EP0545999B1 (de) 1997-06-04
PT98711B (pt) 1999-01-29
AU8417091A (en) 1992-03-17
JPH06500084A (ja) 1994-01-06
WO1992003477A1 (en) 1992-03-05

Similar Documents

Publication Publication Date Title
ATE154073T1 (de) Prozess für die herstellung von biologisch aktivem igf-1 durch verwendung von amino-terminal verlängertem igf-1
ATE218572T1 (de) Verfahren zur herstellung von cefdinir
EP0111389A3 (de) Wesentlich sauberes Schweinewachstumshormon, DNS-Sequenzen dafür und Expressionsvektoren und transfektierte Mikroorganismen zur Herstellung von Schweinewachstumshormon
ZA929539B (en) Process for producing/secreting a protein by a transformed mould using expression/secretion regulating regions derived from an aspergillus endoxylanase II G
ATE283864T1 (de) Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor
ATE174602T1 (de) Verfahren zur herstellung von kristallen des wachstumshormones und die so erhaltenen kristalle
ATE82328T1 (de) Methode fuer selektiven zuwachs des anteils der gewoehnlichen hauptkomponente des antibiotischen komplexes a 40926.
ATE116636T1 (de) Verfahren zur herstellung von 2,6- dichlordiphenylaminessigsäurederivaten.
EP0280407A3 (de) Verfahren zur Herstellung rekombinanter Polypeptide mit Schweine-Wachstumshormonaktivität
DE59304218D1 (de) Neues verfahren zur herstellung von beta-carbolinen
DE3883911D1 (de) Verfahren zur Herstellung von Orotsäure durch Fermentierung.
ES8506092A1 (es) Un metodo de producir un precursor del factor de liberacion de la hormona del crecimiento humana
ATE364088T1 (de) Verfahren zur herstellung von pharmazeutisch aktiver, rekombinanter urokinase umfassend die verwendung von buttersäure oder deren salze
KR100214903B1 (en) Process for producing aminomethanephosphonic acid and aminomethylphosphinic acids
EP0239075A3 (de) Verfahren zur Herstellung eines Fischwachstumshormon-Polypeptids
ATE213234T1 (de) Verfahren zur herstellung von 3-amino-1,2,4- benzotriazindioxide
FR2741348B1 (fr) Nouveau procede de fabrication du palatinitol
ES2045830T3 (es) Procedimiento de preparacion de tensioactivos no ionicos a partir de 1,2-isopropiliden-3-epoxipropil-glicerol y un acido carboxilico.
GR3001086T3 (en) Substituted dioxanones, method for preparing same and use thereof
ATE47427T1 (de) Verfahren zur herstellung von arphamenin mit hoher ausbeute.
ATE10623T1 (de) Verfahren zur herstellung von l-prolin.
ATE319849T1 (de) Verfahren zur herstellung vom ampicillin
ATE25266T1 (de) Verfahren zur biotechnologischen herstellung von l-aepfelsaeure.
HUT47116A (en) Process for producing biotin-pentafluorophenyl esters
DE3667464D1 (de) Verfahren zur herstellung von 2-acyl-3,4-dialkoxyanilinen.